ClinicalTrials.gg
CompletedNCT05592262Updated Dec 19, 2022

Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects

A Phase 1 interventional study of SHR2554 and SHR2554 in Malignant Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of the study is to assess the effect of food on the pharmacokinetics, and safety of SHR2554 Tablets in healthy subjects.

02

Conditions studied

  • Malignant Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged between 18 and 45 (inclusive) at the time of signing the ;
  2. Body weight ≥ 50.0 kg for men and body weight ≥ 45.0 kg for women, and (BMI) within the range of 19.0 to 26.0 kg /m2 (inclusive);
  3. The mean value of three 12-lead tests was normal or abnormal but not , the time limit from Q wave to T wave was \< 430 msec for male (), and \< 450 msec for female (QTcF), and the heart rate was in the normal range or abnormal but not clinically significant.
  4. (CLCr) ≥80 mL/min, and creatinine is less than or equal to the value;
  5. Participants should have no fertility plan from signing the informed consent until 6 months after the last medication, take effective measures voluntarily and have no sperm donation plan. The serum HCG test of fertile women must be negative before Screening;
  6. Participants should sign the informed consent before the study, and fully understand the content, process and possible adverse reactions of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with abnormal vital signs (systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<50 mmHg or >90 mmHg) or abnormal physical examination, laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead and other tests with clinical significance;
  2. Abnormal X-ray examination with clinical significance;
  3. surface antigen, antibody and treponema pallidum antibody are positive or antibody is not negative;
  4. Allergic constitution, including history of severe drug allergy or drug allergy; Allergic history to SHR2554 tablets or the thereof;
  5. Previous history of cardiovascular diseases such as myocarditis, coronary heart disease, pathological arrhythmia, stroke, etc.;
  6. Lung diseases, including invasive lung disease, pneumonia, dyspnea, etc.;
  7. History of chronic kidney disease, renal insufficiency, and renal anemia;
  8. History of dysphagia or any gastrointestinal disease that affects drug absorption;
  9. Any uncontrolled peptic ulcer, colitis, pancreatitis, etc.;
  10. Other important organs of primary diseases, such as the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism, and clear history of musculoskeletal system including but not limited to tumor patient or a history of cancer, such as not good control of diabetes, high blood pressure, etc.), the researchers think that don't fit for the researchers;
  11. Patients who had undergone any surgery that would affect drug absorption, distribution, metabolism, or excretion within 3 months prior to screening;
  12. Took hepatotoxic drugs (e.g. Dapsone, erythromycin, fluconazole, ketoconazole, rifampin) within 6 months before screening;
  13. Candidates who participated in clinical trials within 3 months before screening;
  14. Took any drug that alters the activity of liver enzymes within 28 days prior to taking the study drug;
  15. Took any prescription or over-the-counter medications in the 7 days prior to taking the study drug;
  16. Took any vitamin products or herbs in the 7 days prior to taking the study drug;
  17. History of substance abuse, drug use and/or alcohol abuse: a history of substance abuse in the 6 months prior to screening, or a positive urine substance abuse screening test in the screening/baseline period, or drug use in the 3 months prior to screening; Heavy drinkers (14 units of alcohol per week: 1 unit = 285mL beer, 25mL liquor, or 100mL wine; Smoking ≥5 cigarettes per day), or having a positive alcohol breath test during the screening period/baseline, or being unable to smoke or abstain during the trial;
  18. Drinking grapefruit juice, beverages containing xanthine, caffeine, alcohol, strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion within 48 hours before taking the study drug;
  19. Participants who donated blood ≥400 mL or lost blood ≥400 mL within 3 months before screening, or received blood transfusion;
  20. Patients with a history of needle sickness and blood sickness have difficulty in blood collection or cannot tolerate venipuncture blood collection;
  21. Other factors considered by the investigator to be inappropriate for trial participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR2554

  • Experimental
    Treatment group B

    Drug: SHR2554

Interventions

  • On an empty stomach - after meals

  • After meals - on an empty stomach

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters of SHR2554: Cmax

    Time frame: day 1 to day 10

  2. Pharmacokinetic parameters of SHR2554: AUC0-t

    Time frame: day 1 to day 10

  3. Pharmacokinetic parameters of SHR2554: AUC0-∞ (if applicable)

    Time frame: day 1 to day 10

Secondary outcomes

  1. Pharmacokinetic parameters of SHR2554: Tmax

    Time frame: day 1 to day 10

  2. Pharmacokinetic parameters of SHR2554: t1/2

    Time frame: day 1 to day 10

  3. Pharmacokinetic parameters of SHR2554: CL/F

    Time frame: day 1 to day 10

  4. Pharmacokinetic parameters of SHR2554: Vz/F

    Time frame: day 1 to day 10

  5. The incidence and severity of adverse events/serious adverse events.

    Time frame: from ICF signing date to approximate day 17

07

Study locations

1 site
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Dec 2022, 0 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 0 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 24, 2022
StartActual
Nov 15, 2022
Primary completionActual
Dec 14, 2022
CompletionActual
Dec 14, 2022
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05592262
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Nov 15, 2022
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Last update
Dec 19, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion